Litcius/Paper detail

Safety and immunogenicity of the intranasal H3N2 M2-deficient single-replication influenza vaccine alone or coadministered with an inactivated influenza vaccine (Fluzone High-Dose Quadrivalent) in adults aged 65–85 years in the USA: a multicentre, randomised, double-blind, double-dummy, phase 1b trial

Joseph Eiden, Carlos Fierro, Alexander White, Matthew C. Davis, Margaret Rhee, Mark Turner, Bryan Murray, Renee Herber, Roger Aitchison, David Marshall, Michael J. Moser, Robert B. Belshe, Harry B. Greenberg, Kathleen Coelingh, Yoshihiro Kawaoka, Gabriele Neumann, Pamuk Bilsel

2024The Lancet Infectious Diseases12 citationsDOI

Topics & Concepts

ImmunogenicityNasal administrationVirologyInfluenza vaccineMedicineReplication (statistics)Live attenuated influenza vaccineVaccinationImmunologyImmune systemInfluenza Virus Research StudiesPneumonia and Respiratory InfectionsRespiratory viral infections research
Safety and immunogenicity of the intranasal H3N2 M2-deficient single-replication influenza vaccine alone or coadministered with an inactivated influenza vaccine (Fluzone High-Dose Quadrivalent) in adults aged 65–85 years in the USA: a multicentre, randomised, double-blind, double-dummy, phase 1b trial | Litcius